Covaxin developed by Bharat Biotech, Hyderabad has commended its Human clinical trials in association with Indian Council of Medical Research (ICMR) at Jeevan Rekha Hospital in Belagavi for treatment of COVID-19.
ICMR had identified 12 locations in the country which includes the Jeevan Rekha at Belagavi and vaccine dose has been administered to 4 volunteers as of now.
two male and two female volunteers have been administered the vaccine here at Belagavi and they were advancement on expected lines with no reactions being witnessed after four days of administering the vaccine.
The second dose will be administered to them on the 14th day after the first dose has been administered.
Those between 18 and 55 years of age with no heart, kidney, liver or lung illness and no uncontrolled diabetes or hypertension are eligible for the study. Routine investigations like liver, kidney function, Covid-19 detection, and rapid antibody tests are performed on volunteers before recruitment.
Covaxin has been developed by Bharat Biotech, a pharmaceutical company based in Hyderabad. The development of the vaccine was done in collaboration with the ICMR and its Pune-based National Institute of Virology, the report added. The phase I and II human clinical trials were approved by the Drug Controller General of India earlier.